To further explore potential AAT targets for 18F-Fluciclovine uptake in our in vivo treatment-resistant prostate cancer model, we utilised data from transcriptomic analysis of prostate orthografts [17]. This evidence concerns the gene SERPINA1 and prostate carcinoma.